Resources from the same session
LBA25 - Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
Presenter: Stefan Kasper-Virchow
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
502O - Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial
Presenter: David Tougeron
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
505O - Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
Presenter: Salvatore Siena
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
Q&A
Session: Proffered paper session 2: GI tumours, lower
Resources:
Webcast
LBA26 - SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
Presenter: Kimmie Ng
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
506O - Evaluation of risk of disease progression in first-line therapy of unresected metastatic colorectal cancer to guide intervals of radiological assessment: An analysis of eleven randomized trials by AIO and GONO
Presenter: Marco Germani
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA26 and 506O
Presenter: Michel Ducreux
Session: Proffered paper session 2: GI tumours, lower
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session 2: GI tumours, lower
Resources:
Webcast